Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.54 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | MPO | P05164 | 5/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | CDC25B | P30305 | 3/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4245362 | 0.84 | TAS2R14 (0.74) | TAS2R14AKR1C3AKR1C2MPO | |
| SCHEMBL12477213 | 0.82 | SMO (0.44) | TAS2R14GRM4 | |
| SCHEMBL12477066 | 0.81 | EPHX2 (0.49) | — | |
| SCHEMBL12697330 | 0.80 | MPO (0.67) | AKR1C3AKR1C2AKR1C4AKR1C1MPO | |
| SCHEMBL12697327 | 0.78 | AKR1C3 (0.60) | TAS2R14AKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL12697328 | 0.77 | AKR1C3 (0.52) | TAS2R14AKR1C3AKR1C2AKR1C4AKR1C1 | |
| SCHEMBL14486544 | 0.76 | AKR1C3 (0.60) | AKR1C3AKR1C2AKR1C4AKR1C1CDC25B | |
| SCHEMBL12697326 | 0.75 | AKR1C3 (0.60) | AKR1C3AKR1C2AKR1C4AKR1C1MPO | |
| SCHEMBL14554749 | 0.74 | TAS2R14 (0.43) | TAS2R14GRM4AR | |
| SCHEMBL12697329 | 0.73 | MAPT (0.55) | AKR1C3AKR1C2AKR1C4AKR1C1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| WO-2013005168-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012090177-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | TAS2R14 879/4885AKR1C3 1154/4885AKR1C2 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.